Search results
Showing 2656 to 2670 of 8935 results
Awaiting development Reference number: GID-TA11976 Expected publication date: TBC
Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [TSID12358]
Awaiting development Reference number: GID-TA11977 Expected publication date: TBC
Awaiting development Reference number: GID-TA11919 Expected publication date: TBC
In development Reference number: GID-TA11694 Expected publication date: TBC
Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism
In development Reference number: GID-HTG10169 Expected publication date: TBC
In development Reference number: GID-TA11385 Expected publication date: TBC
In development Reference number: GID-TA11566 Expected publication date: 10 June 2026
Nivolumab with ipilimumab for untreated advanced hepatocellular carcinoma [ID6239]
In development Reference number: GID-TA11116 Expected publication date: 11 November 2026
Awaiting development Reference number: GID-TA11978 Expected publication date: TBC
We are listening to your views on this Technology appraisal guidance. Comments close 3 March 2026.
We are listening to your views on this Technology appraisal guidance. Comments close 23 February 2026.
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making
Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..
Summary of the evidence on green tea (Camellia sinensis) leaf extract 10% ointment for treating external genital and perianal warts to inform local NHS planning